Cervical Cancer

The government is likely to begin administering anti-cervical cancer vaccine in girls aged nine to 14 years in six states in June, official sources said on Sunday. In the first phase of the vaccination campaign, 2.55 crore girls are targeted to be administered the human papillomavirus (HPV) vaccine in Karnataka, Tamil Nadu, Mizoram, Chhattisgarh, Maharashtra and Uttar Pradesh, an official source told PTI. The Union Health Ministry has drawn a roadmap to roll out HPV vaccine in the universal immunisation programme and is likely to float a global tender in April for 16.02 crore doses to be procured by 2026, official sources said. The Serum Institute's made-in-India vaccine against cervical cancer, CERVAVAC, was launched last month. Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute of India (SII), has written a letter to the Health Ministry its first indigenous HPV vaccine will be available in the private market at an MRP of Rs 2,000 per dose, i

A day after the first indigenously developed Human Papillomavirus vaccine against cervical cancer was launched, Serum Institute of India CEO Adar Poonawalla on Wednesday said the vaccine will be available in small quantity this year and its production will be boosted next year to take care of the needs of the nation. Speaking on the sidelines of an event after presenting the vaccine to Union Health Minister Mansukh Mandaviya, Poonawalla said the vaccine 'CERVAVAC' will be made available through the government programme this year. The vaccine for 9-14-year-old was launched on Tuesday in the presence of Union Home Minister Amit Shah, Poonawalla, and Director of Government and Regulatory Affairs at Serum Institute of India, Prakash K Singh. It will be available at a much lower price than the internationally branded vaccines available in the market, Singh had said earlier. The vaccine will be included in the National Immunisation Programme by mid-2023, government officials had said.

Lancet report titled, "Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative," highlights glaring reality

India would be in a position to roll out the indigenously developed Human Papillomavirus Vaccine (HPV) against cervical cancer for girls in the age group of 914 under the National Immunisation Programme by mid-2023, NTAGI chairperson Dr N K Arora said. The CERVAVAC vaccine is likely to be launched by the Serum Institute of India (SII) in April next year and will be available at a much lower price than the international vaccines available in the market, Prakash Kumar Singh, Director, Government and Regulatory Affairs at the SII said on the sidelines of the South Asia meeting on HPV here. The vaccine has received the DCGI's approval and been cleared by the government advisory panel National Technical Advisory Group on Immunisation (NTAGI) for use in the public health programme, Dr Arora told PTI. At present, the country is fully dependent on foreign manufacturers for the vaccine. Three foreign companies manufacture the HPV vaccine out of which two firms sell their vaccines in India. .

Dr Singh said that WHO has called for action in several key areas to achieve the elimination target of four or less cases per 100,000 women

The locally developed Ceravac can play a critical role in the efficacy of the National Immunisation Mission

Serum India's product made in collaboration with state-run biotechnology department, expected to bring down prices

India's first indigenously developed quadrivalent Human Papilloma Virus (HPV) vaccine for the prevention of cervical cancer will be launched here on Thursday, officials said on Wednesday The Drugs Controller General of India (DCGI) had last month granted market authorisation to Serum Institute of India (SII) to manufacture an indigenously-developed vaccine against cervical cancer. Union Minister of Science and Technology Jitendra Singh will launch the vaccine at IIC Delhi. SII CEO Adar Poonawalla will be present at the event, the officials said. According to the officials, the qHPV vaccine CERVAVAC has demonstrated robust antibody response that is nearly 1,000 times higher than the baseline against all targeted HPV types and in all dose and age groups. Cervical cancer in India ranks as the second most frequent cancer among women between 15 and 44 years of age. The DCGI's approval had come following recommendation by the Subject Expert Committee (SEC) on COVID-19 of the CDSCO on Ju

SII's CEO Adar Poonawalla tweeted to make the announcement, 'For the first time, there will be an Indian HPV vaccine to treat cervical cancer in women that is both affordable and accessible'

Country now depends on foreign companies and Serum's product is likely to bring down prices.

The HPV vaccine, administered to pre-pubescent girls to prevent cervical cancer, has received considerable bad press over its 14 years

The leading cause of cervical cancer is HPV, found in about 99 per cent of cervical cancer cases

It's a cheap screening device that's gaining acceptance over the more intrusive speculum for its ability to capture cancerous and pre-cancerous conditions using high-quality pictures of the cervix

Nimmi Ramanujam's low-cost diagnostic device could transform women's health in poor countries, but the engineer says she drew on her musical skills for inspiration too.

Cervical cancer surfaces from the cervix and is primarily caused by HPV, which most commonly is contracted after sexual contact